JP7395463B2 - 腫瘍微小環境における免疫応答を増強するための治療剤および方法 - Google Patents

腫瘍微小環境における免疫応答を増強するための治療剤および方法 Download PDF

Info

Publication number
JP7395463B2
JP7395463B2 JP2020502514A JP2020502514A JP7395463B2 JP 7395463 B2 JP7395463 B2 JP 7395463B2 JP 2020502514 A JP2020502514 A JP 2020502514A JP 2020502514 A JP2020502514 A JP 2020502514A JP 7395463 B2 JP7395463 B2 JP 7395463B2
Authority
JP
Japan
Prior art keywords
cancer
antibody
antibodies
amino acid
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020502514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020527581A (ja
JP2020527581A5 (enExample
Inventor
ワング，ジェイ
Original Assignee
リビジェン バイオファーマ ホールディングス リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リビジェン バイオファーマ ホールディングス リミテッド filed Critical リビジェン バイオファーマ ホールディングス リミテッド
Publication of JP2020527581A publication Critical patent/JP2020527581A/ja
Publication of JP2020527581A5 publication Critical patent/JP2020527581A5/ja
Application granted granted Critical
Publication of JP7395463B2 publication Critical patent/JP7395463B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1825—Fibroblast growth factor [FGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2020502514A 2017-03-28 2018-03-28 腫瘍微小環境における免疫応答を増強するための治療剤および方法 Active JP7395463B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762477661P 2017-03-28 2017-03-28
US62/477,661 2017-03-28
PCT/US2018/024872 WO2018183520A1 (en) 2017-03-28 2018-03-28 Therapeutic agents and methods for enhancing immune responses in tumor microenvironment

Publications (3)

Publication Number Publication Date
JP2020527581A JP2020527581A (ja) 2020-09-10
JP2020527581A5 JP2020527581A5 (enExample) 2021-05-06
JP7395463B2 true JP7395463B2 (ja) 2023-12-11

Family

ID=63677056

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020502514A Active JP7395463B2 (ja) 2017-03-28 2018-03-28 腫瘍微小環境における免疫応答を増強するための治療剤および方法

Country Status (8)

Country Link
US (1) US12024560B2 (enExample)
EP (1) EP3601333A4 (enExample)
JP (1) JP7395463B2 (enExample)
KR (1) KR20200006526A (enExample)
CN (7) CN113603780B (enExample)
AU (1) AU2018244574A1 (enExample)
CA (1) CA3058185A1 (enExample)
WO (1) WO2018183520A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7682102B2 (ja) * 2019-05-10 2025-05-23 リビジェン バイオファーマ ホールディングス リミテッド ヒト化抗ｃｄ１３７抗体およびその使用
EP4071167A4 (en) * 2019-12-03 2024-03-06 Shanghai Jiao Tong University School of Medicine ANTIBODIES FC REGION WITH INCREASED FCGRIB AFFINITY
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
CN114106174A (zh) * 2020-08-27 2022-03-01 苏州景涞医疗科技有限公司 低毒性抗ox40抗体、其药物组合物及应用
JP2024500945A (ja) * 2020-12-23 2024-01-10 マクファーレン バーネット インスティテュート フォー メディカル リサーチ アンド パブリック ヘルス リミテッド ＦｃガンマＲＩＩｂに対する親和性を有する修飾免疫グロブリン及びその使用方法
CA3173944A1 (en) 2021-01-13 2022-07-21 Visterra, Inc. Humanized complement 5a receptor 1 antibodies and methods of use thereof
CN117295760A (zh) * 2021-05-07 2023-12-26 信达生物制药(苏州)有限公司 与Fc受体结合改变的Fc突变体
CN121843714A (zh) 2023-08-11 2026-04-10 派拉冈医疗公司 Tl1a结合抗体及使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
JP2016026215A (ja) 2007-09-26 2016-02-12 中外製薬株式会社 抗体定常領域改変体

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040132101A1 (en) * 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
US7960512B2 (en) 2003-01-09 2011-06-14 Macrogenics, Inc. Identification and engineering of antibodies with variant Fc regions and methods of using same
US8388955B2 (en) 2003-03-03 2013-03-05 Xencor, Inc. Fc variants
US8101720B2 (en) * 2004-10-21 2012-01-24 Xencor, Inc. Immunoglobulin insertions, deletions and substitutions
WO2006085967A2 (en) * 2004-07-09 2006-08-17 Xencor, Inc. OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
CN101098890B (zh) * 2004-11-12 2012-07-18 赞科股份有限公司 对FcRn的结合被改变的Fc变体
WO2006105338A2 (en) 2005-03-31 2006-10-05 Xencor, Inc. Fc VARIANTS WITH OPTIMIZED PROPERTIES
EP2144931A2 (en) 2007-04-04 2010-01-20 The Government Of The U.S.A, As Represented By The Secretary, Dept. Of Health And Human Services Monoclonal antibodies against dengue and other viruses with deletion in fc region
JP2010526868A (ja) * 2007-05-14 2010-08-05 ノビミューン エスアー 改変されたエフェクター機能を有するＦｃ受容体結合ポリペプチド
EP2176298B1 (en) * 2007-05-30 2017-11-15 Xencor, Inc. Methods and compositions for inhibiting cd32b expressing cells
ES3006441T3 (en) * 2007-09-14 2025-03-18 Amgen Inc Homogeneous antibody populations
JP2013528357A (ja) * 2010-03-29 2013-07-11 ザイムワークス，インコーポレイテッド 強化又は抑制されたエフェクター機能を有する抗体
WO2012087928A2 (en) * 2010-12-20 2012-06-28 The Rockefeller University Modulating agonistic tnfr antibodies
ES2623912T3 (es) * 2010-12-23 2017-07-12 Janssen Biotech, Inc. Mutantes FC de anticuerpo activo resistente a proteasa
MX2018012383A (es) * 2011-03-30 2023-03-07 Chugai Pharmaceutical Co Ltd Método para alterar la retención en plasma e inmunogenicidad de la molécula de union al antígeno.
UA117901C2 (uk) * 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
HUE033245T2 (hu) 2011-12-19 2017-11-28 Synimmune Gmbh Bispecifikus ellenanyag molekula
SG10201709559PA (en) * 2012-08-24 2017-12-28 Chugai Pharmaceutical Co Ltd Fcγriib-specific fc region variant
GB201216649D0 (en) * 2012-09-18 2012-10-31 Univ Birmingham Agents and methods
CA2891764A1 (en) * 2012-11-19 2014-05-22 Baliopharm Ag Recombinant bispecific antibody binding to cd20 and cd95
HK1220470A1 (zh) 2013-03-15 2017-05-05 Abbvie Biotechnology Ltd. 抗cd25抗体及其用途
US20140377253A1 (en) 2013-03-15 2014-12-25 Abbvie Biotherapeutics Inc. Fc variants
SG10201708048XA (en) * 2013-03-18 2017-10-30 Biocerox Prod Bv Humanized anti-cd134 (ox40) antibodies and uses thereof
CN105246914B (zh) * 2013-04-02 2021-08-27 中外制药株式会社 Fc区变体
WO2014177459A2 (en) * 2013-04-29 2014-11-06 F. Hoffmann-La Roche Ag Fc-receptor binding modified asymmetric antibodies and methods of use
GB201308658D0 (en) * 2013-05-14 2013-06-26 Isis Innovation Antibodies
EP3041863A4 (en) * 2013-09-05 2017-08-16 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
CA2939201A1 (en) * 2014-03-05 2015-09-11 Ucb Biopharma Sprl Multimeric fc proteins
MX2016010951A (es) 2014-03-05 2016-11-29 Ucb Biopharma Sprl Proteinas de fc multimericas.
EP2990416B1 (en) * 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
AU2015349878A1 (en) * 2014-11-21 2017-05-25 Bristol-Myers Squibb Company Antibodies against CD73 and uses thereof
AU2016276981B2 (en) * 2015-06-12 2022-10-06 Alector Llc Anti-CD33 antibodies and methods of use thereof
KR20180054639A (ko) * 2015-08-28 2018-05-24 알렉터 엘엘씨 항-siglec-7 항체 및 이의 사용 방법
BR112018074453A2 (pt) 2016-05-27 2019-03-19 Abbvie Biotherapeutics Inc. proteínas de ligação biespecíficas ligando uma protéina imunomoduladora e um antígeno tumoral
CN112996818B (zh) * 2018-09-28 2022-06-21 礼进生物医药科技（上海）有限公司 具有经过工程化的Fc结构域的抗CD40结合分子及其治疗用途
JP7682102B2 (ja) * 2019-05-10 2025-05-23 リビジェン バイオファーマ ホールディングス リミテッド ヒト化抗ｃｄ１３７抗体およびその使用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008092117A2 (en) 2007-01-25 2008-07-31 Xencor, Inc. Immunoglobulins with modifications in the fcr binding region
JP2016026215A (ja) 2007-09-26 2016-02-12 中外製薬株式会社 抗体定常領域改変体

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
Biology of Reproduction，2010年，vol.83，p.481-487
Journal of Biological Chemistry，2015年，vol.290, no.9，p.5462-5469
Nature Communications，2016年，7:13696. doi:10.1038/ncomms13696，p.1-15
Pathology-Research and Proctice，2010年，vol.206，p.631-641

Also Published As

Publication number Publication date
JP2020527581A (ja) 2020-09-10
CN113480654A (zh) 2021-10-08
CN113480654B (zh) 2022-06-10
CA3058185A1 (en) 2018-10-04
CN113603780A (zh) 2021-11-05
WO2018183520A1 (en) 2018-10-04
EP3601333A4 (en) 2021-05-26
CN113480655A (zh) 2021-10-08
CN110546162B (zh) 2021-09-07
EP3601333A1 (en) 2020-02-05
US12024560B2 (en) 2024-07-02
CN113603780B (zh) 2022-07-01
KR20200006526A (ko) 2020-01-20
CN113603781B (zh) 2022-09-02
US20200392227A1 (en) 2020-12-17
WO2018183520A8 (en) 2019-10-31
CN113480655B (zh) 2022-05-31
CN113336849A (zh) 2021-09-03
AU2018244574A1 (en) 2019-10-31
CN113603781A (zh) 2021-11-05
CN110546162A (zh) 2019-12-06
CN113201071A (zh) 2021-08-03

Similar Documents

Publication Publication Date Title
JP7395463B2 (ja) 腫瘍微小環境における免疫応答を増強するための治療剤および方法
JP2022532173A (ja) ヒト化抗ｃｄ１３７抗体およびその使用
CN116057070A (zh) 抗cd40结合分子和包括其的双特异性抗体
CN111542342B (zh) 抗cd137抗体及其用途
JP7626698B2 (ja) 操作されたＦｃドメインを有する抗ＣＤ４０結合分子およびその治療用途
CN113039201A (zh) 具有经过工程化的Fc结构域的抗CD137结合分子及其治疗用途
US11186648B2 (en) Anti-CD40 antibody having engineered Fc domains and therapeutic uses thereof
US20210355220A1 (en) Antibodies specific to ctla-4 and uses thereof
KR20230015348A (ko) Th2 개재성 질환을 치료 또는 예방하기 위한 PD-1 작용제 함유 의약 조성물
KR20230107294A (ko) 항-cd137 결합 분자를 포함하는 이중-특이적 항체
CN106661105A (zh) 用il‑20拮抗剂治疗炎性疼痛
KR20210005082A (ko) 항-cd40 항체 및 이의 용도
HK40068698B (zh) 人源化抗cd137抗体及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20191209

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200421

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210323

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210323

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220118

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20220120

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220617

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221128

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20230125

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230227

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230509

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230908

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20231026

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20231107

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20231129

R150 Certificate of patent or registration of utility model

Ref document number: 7395463

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150